Navigation Links
Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
Date:3/13/2008

SCHAUMBURG, Ill., March 13 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company today announced that it has launched Cefazolin for injection, USP, an essential antibiotic used to treat serious infections. Sagent's Cefazolin for injection will be available in 1g single dose vials and 10g pharmacy bulk package vials. According to IMS data, sales of Cefazolin in the United States in 2006 were approximately $69 million.

The introduction of Cefazolin for injection marks the second product launch in three months from Sagent's pipeline of more than 200 products. The launch of Cefazolin for injection follows Sagent's December 2007 introduction of the first full-line of latex-free, multi-source prefilled, ready-to-use, 6 mg and 12 mg, adenosine syringes in the market. Sagent will begin marketing and shipping Cefazolin immediately.

"The launch of Cefazolin, the first product to emerge from our extensive anti-infective pipeline, marks further progress toward Sagent's ultimate goal of becoming a leader in the injectables marketplace," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "This product provides our customers another sourcing option for this important antibiotic and, as with all Sagent products, offers enhanced labeling intended to optimize product safety and increase efficiency in the hospital."

About Cefazolin

Cefazolin for injection, USP, is the generic equivalent of GlaxoSmithKline's ANCEF(R), an antibiotic used to treat bacterial infections. Cefazolin for injection, USP, is indicated for serious infections such as those of the respiratory, biliary and urinary tracts, skin and skin structure infections, bone and joint infections, and other infections caused by various strains of streptococci. Prophylactic Cefazolin for injection, USP, preoperative, intraopertative and postoperative administration can be effective in reducing the incidence of
'/>"/>

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that it will release fourth ... on Tuesday, March 10, 2015 after the close of ... conference call and webcast on Tuesday, March 10, 2015 ... discuss the results and recent corporate developments. ...
(Date:3/2/2015)... 2015 Global Stem Cells ... with Shenzhen HANK Bioengineering Co., Ltd. and its ... will establish a stem cells training course in ... September 2015. , Shenzhen HANK is a biotechnology ... scientist, microbiologist and virologist, to integrate research, development, ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO ... episodes of The GMO TRUTH podcast on both ITunes and ... continues its mission to discover the truth and change the ... “uncover the truth about the GMOs in our food supply,” ... Podcast is an expansion of the documentary/investigative film-making methodology in ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
... , , LOS ANGELES, Aug. 6 ... an 82 year-old Chinese female immigrant who suffered Stevens-Johnson Syndrome/Toxic Epidermal ... Defendant, an osteopathic physician and registered pharmacist, prescribed it to her ... did not have gout. The doctor claimed that she told ...
... , , OMAHA, Neb., Aug. 6 Transgenomic Inc. (OTC ... What: Transgenomic Inc. Second Quarter 2009 Earnings Release, ... Wednesday, August 12, 2009 @ 5:00 p.m. Eastern, Where: ... the Internet -- Simply log on to the web at the, ...
... , , , , ... drugs to combat Alzheimer,s began journey 8 years ago , , ... of a million" , , NEW YORK, Aug. 6 ... (ADDF) , have achieved a significant milestone in their development as they advance ...
Cached Biology Technology:The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict 2Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 2PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 3
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... surrounds the DNA of our cells could help develop treatments ... have discovered that the proteins within this coating known ... different organs of the body. This variation ... proteins in the protective seal to cause illness in some ...
... Daejeon, Republic of Korea, February 26, 2013The Korea Advanced ... a global energy and petrochemicals enterprise, signed on February ... Agreement) on joint collaborations in research and development of ... Agreement was subsequently concluded upon the signing of the ...
... is faced with some of the world,s worst pollution. Until ... a major contributor to that pollution human-caused nitrogen emissions ... biology professor and Stanford Woods Institute senior fellow Peter Vitousek ... deposited on land and water in China by way of ...
Cached Biology News:Cell discovery could hold key to causes of inherited diseases 2Launched the Saudi Aramco-KAIST CO2 Management Center in Korea 2Stanford scientists help shed light on key component of China's pollution problem 2
...
...
... monoclonal [198C679.2.1] to Presenilin 2 Alzheimer's ... of the disease carry mutations in the ... precursor protein (APP). These disease-linked mutations result ... of amyloid-beta (main component of amyloid deposits ...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
Biology Products: